Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.

Brennan FR, Polli JR, Sathish J, Ramones M, Wolf B, Schlothauer T, Peters SJ, Maier CC, Ji C, Wensel DL, Witcher D, Ryan PC, Manetz TS, Flora A, Soper B, Fogal B, Dzielak L, Wang X, Shastri PN, Price K, Doyle M, Sharda N, Struthers M, Brinkhaus M, Balbino B, Stefanich E, Honda M, Andersen JT, Mitchell-Ryan S, Humphreys DP

Open source

DOI: 10.1080/19420862.2025.2505092
Published: 2025 Dec
Container: mAbs
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/19420862.2025.2505092,
  title = {Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.},
  author = {Brennan FR and Polli JR and Sathish J and Ramones M and Wolf B and Schlothauer T and Peters SJ and Maier CC and Ji C and Wensel DL and Witcher D and Ryan PC and Manetz TS and Flora A and Soper B and Fogal B and Dzielak L and Wang X and Shastri PN and Price K and Doyle M and Sharda N and Struthers M and Brinkhaus M and Balbino B and Stefanich E and Honda M and Andersen JT and Mitchell-Ryan S and Humphreys DP},
  year = {2025},
  journal = {mAbs},
  doi = {10.1080/19420862.2025.2505092},
  url = {https://doi.org/10.1080/19420862.2025.2505092}
}

RIS

TY  - JOUR
TI  - Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.
AU  - Brennan FR
AU  - Polli JR
AU  - Sathish J
AU  - Ramones M
AU  - Wolf B
AU  - Schlothauer T
AU  - Peters SJ
AU  - Maier CC
AU  - Ji C
AU  - Wensel DL
AU  - Witcher D
AU  - Ryan PC
AU  - Manetz TS
AU  - Flora A
AU  - Soper B
AU  - Fogal B
AU  - Dzielak L
AU  - Wang X
AU  - Shastri PN
AU  - Price K
AU  - Doyle M
AU  - Sharda N
AU  - Struthers M
AU  - Brinkhaus M
AU  - Balbino B
AU  - Stefanich E
AU  - Honda M
AU  - Andersen JT
AU  - Mitchell-Ryan S
AU  - Humphreys DP
PY  - 2025
JO  - mAbs
DO  - 10.1080/19420862.2025.2505092
UR  - https://doi.org/10.1080/19420862.2025.2505092
ER  -

APA

FR, B., JR, P., J, S., M, R., B, W., T, S., SJ, P., CC, M., C, J., DL, W., D, W., PC, R., TS, M., A, F., B, S., B, F., L, D., X, W., PN, S., K, P., M, D., N, S., M, S., M, B., B, B., E, S., M, H., JT, A., S, M., & DP, H. (2025). Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.. mAbs. https://doi.org/10.1080/19420862.2025.2505092

Source records

pubmed · retrieved 2026-09-26T09:43:54.506Z